Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Richard W. Joseph; Gurkamal Chatta; Ulka Vaishampayan

doi:10.1016/j.urolonc.2017.01.017

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Richard W. Joseph, Gurkamal Chatta, Ulka Vaishampayan

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

Original language	English (US)
Pages (from-to)	142-148
Number of pages	7
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	35
Issue number	4
DOIs	https://doi.org/10.1016/j.urolonc.2017.01.017
State	Published - Apr 1 2017

Keywords

Advanced renal cell carcinoma
Immune checkpoint inhibitor
Immunotherapy agents
Nivolumab
PD-1 inhibitor
Second-line therapy

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2017.01.017

Cite this

@article{efe225a26a4340729667f5f762883342,

title = "Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice",

abstract = "Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.",

keywords = "Advanced renal cell carcinoma, Immune checkpoint inhibitor, Immunotherapy agents, Nivolumab, PD-1 inhibitor, Second-line therapy",

author = "Joseph, {Richard W.} and Gurkamal Chatta and Ulka Vaishampayan",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = apr,

day = "1",

doi = "10.1016/j.urolonc.2017.01.017",

language = "English (US)",

volume = "35",

pages = "142--148",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Nivolumab treatment for advanced renal cell carcinoma

T2 - Considerations for clinical practice

AU - Joseph, Richard W.

AU - Chatta, Gurkamal

AU - Vaishampayan, Ulka

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

AB - Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

KW - Advanced renal cell carcinoma

KW - Immune checkpoint inhibitor

KW - Immunotherapy agents

KW - Nivolumab

KW - PD-1 inhibitor

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=85014124224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014124224&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2017.01.017

DO - 10.1016/j.urolonc.2017.01.017

M3 - Review article

C2 - 28259541

AN - SCOPUS:85014124224

SN - 1078-1439

VL - 35

SP - 142

EP - 148

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 4

ER -

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this